Imre Pávó

Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial

Stefano Del Prato, Steven E. Kahn, Imre Pávó et al. · The Lancet · 2021 · 642 citations

Medicine, Pharmacology, Pharmacotherapy +16

Differential Effects of Teriparatide on BMD After Treatment With Raloxifene or Alendronate

Bruce Ettinger, San Martín, Gerald Crans et al. · Journal of Bone and Mineral Research · 2004 · 486 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +15

Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial

Hiddo J.L. Heerspink, Naveed Sattar, Imre Pávó et al. · The Lancet Diabetes & Endocrinology · 2022 · 279 citations · Full text

Medicine, Nephrology, Pharmacotherapy +15

Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS‐CVOT design and baseline characteristics

Stephen J. Nicholls, Deepak L. Bhatt, John B. Buse et al. · American Heart Journal · 2023 · 222 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Early Changes in Biochemical Markers of Bone Formation Correlate with Improvements in Bone Structure during Teriparatide Therapy

Harald Dobnig, Adrien Sipos, Yebin Jiang et al. · The Journal of Clinical Endocrinology & Metabolism · 2005 · 193 citations · Full text

Medicine, Orthopedic Surgery, Pharmacology +15